Pre-clinical experimentation and clinical research
Pre-clinical experimentation and clinical research
Contact
Arronax Nantes > Pre-clinical experimentation and clinical research > Our publications

Our publications

  • F-18-fdg pet/ct at baseline in dlbcl patients enrolled in the gained protocol: A machine learning study to assess the usefulness of combining clinical, conventional and radiomics features to predict the 2-years pfs and survival
    Thomas Carlier, Gauthier Frecon, Diana Mateus, Mira Rizkallah, Francoise Kraeber-Bodéré, S Kanoun, P Blanc-Durand, E Itti, S Le Gouill, R Casasnovas, and others
    European Journal Of Nuclear Medicine And Molecular Imaging, Annual Congress of the European Association of Nuclear Medicine, Barcelona (Spain), October 15-19, 2022

  • A multi-task learning approach for prediction of treatment response in multiple myeloma
    K.L. Nguyen, Bastien Jamet, Clement Bailly, Caroline Bodet-Milin, Francoise Kraeber-Bodéré, Philipe Moreau, Cyrille Touzeau, Thomas Carlier, and Diana Mateus
    IEEE Nuclear Science Symposium, Medical Imaging Conference, Milan (Italy), November 2022

  • Nested admm for pet reconstruction with two constraints : Deep image prior and non-negativity in projection space
    Alexandre Merasli, T. Liu, Thomas Carlier, Diana Mateus, Mael Millardet, Said Moussaoui, and Simon Stute
    IEEE Nuclear Science Symposium, Medical Imaging Conference, Milan (Italy), November 2022

  • Prognostic value of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 Trial
    C. Morvant, C. Bailly, T. Carlier, G. Frecon, F. Kraeber-Bodéré, S. Le Gouill, E. Macintyre, C. Bodet-Milin,
    J. Nucl. Med. Meeting Abstracts, SNM congress 2022, Vancouver, Canada

  • PET Imaging for MRD Evaluation in Multiple Myeloma
    CE13: Therapy Assessment in Oncology
    SNM congress 2022, Vancouver, Canada

  • FDG-PET/CT in Lymphoma: Where Do We Go Now?, Al Tabaa, Y ; Bailly, C ; Kanoun, S, Cancers (Basel), 2021, 13
    https://doi.org/10.3390/cancers13205222

  • Immuno-PET: Design options and clinical proof-of-concept, Lugat, A ; Bailly, C ; Chérel, M ; Rousseau, C ; Kraeber-Bodéré, F ; Bodet-Milin, C & al, Front Med (Lausanne), 2022, 9, 1026083
    https://doi.org/10.3389/fmed.2022.1026083

  • Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma, Bailly, C ; Carlier, T ; Tessoulin, B ; Gastinne, T ; Kraeber-Bodere, F ; Le Gouill, S & al , Hematol Oncol, 2022, 40, 796-800
    https://doi.org/10.1002/hon.2965

  • Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study, Alberge JB, Kraeber-Bodéré F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Béné MC, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Chérel M, Moreau P, Minvielle S, Bailly C. (DA), J Nucl Med, 2022, 63, 1008-1013
    https://doi.org/10.2967/jnumed.121.262884

  • Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study, Kraeber-Bodéré, F ; Zweegman, S ; Perrot, A ; Hulin, C ; Caillot, D ; Facon, T & al , Haematologica, 2022
    https://doi.org/10.3324/haematol.2021.280051

see more results